HCPCS Level II drug code
J2354 — Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg
In short
J2354 is the HCPCS Level II code for injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg. CMS assigns NDCs for Octreotide Acetate and Sandostatin to it. One billing unit is 25 mcg. The Medicare Part B payment limit is $0.574 per unit (October 1, 2026 through December 31, 2026).
Code
CMS HCPCS file- Descriptor
- Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg
- Short descriptor
- Octreotide inj, non-depot
- Code set
- HCPCS Level II, maintained by CMS
- Effective
- Jan 1, 2004
The billing unit is read from the descriptor. Confirm it against the CMS file before billing.
Medicare Part B payment limit
CMS ASP fileEffective October 1, 2026 through December 31, 2026. Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data. A payment limit is not a coverage decision; the Medicare contractor decides coverage. CMS ASP pricing files
Units and claim line
Units = dose given ÷ 25 mcg. For example, 2500 mcg is 100 units. Enter the dose to get the units and the NDC line for the CMS-1500 and the 837P.
Enter the dose given to build the claim line.
NDCs billed under J2354
CMS’s ASP NDC–HCPCS crosswalk (effective October 1, 2026 through December 31, 2026) assigns 36 NDCs to J2354 for Octreotide Acetate and Sandostatin. Billing units per package are CMS’s figures for this code’s unit.
| Drug | NDC (11-digit) | Labeler | Package | Billing units per package |
|---|---|---|---|---|
| Octreotide Acetate | 00641-6174-10 | Hikma Pharmaceuticals USA Inc. | 10 × 1 | 20 |
| Octreotide Acetate | 00641-6175-10 | Hikma Pharmaceuticals USA Inc. | 10 × 1 | 40 |
| Octreotide Acetate | 00641-6176-10 | Hikma Pharmaceuticals USA Inc. | 10 × 1 | 200 |
| Octreotide Acetate | 00641-6177-01 | Hikma Pharmaceuticals USA Inc. | 5 | 40 |
| Octreotide Acetate | 00641-6178-01 | Hikma Pharmaceuticals USA Inc. | 5 | 200 |
| Octreotide Acetate | 23155-0685-31 | Heritage Pharmaceuticals Inc. | 5 | 40 |
| Octreotide Acetate | 23155-0686-31 | Heritage Pharmaceuticals Inc. | 5 | 200 |
| Octreotide Acetate | 23155-0687-41 | Heritage Pharmaceuticals Inc. | 10 × 1 | 20 |
| Octreotide Acetate | 23155-0688-41 | Heritage Pharmaceuticals Inc. | 10 × 1 | 40 |
| Octreotide Acetate | 23155-0689-41 | Heritage Pharmaceuticals Inc. | 10 × 1 | 200 |
| Octreotide Acetate | 25021-0451-01 | Sagent Pharmaceuticals | 10 × 1 | 20 |
| Octreotide Acetate | 25021-0452-01 | Sagent Pharmaceuticals | 10 × 1 | 40 |
| Octreotide Acetate | 25021-0453-01 | Sagent Pharmaceuticals | 10 × 1 | 200 |
| Octreotide Acetate | 25021-0454-05 | Sagent Pharmaceuticals | 5 | 40 |
| Octreotide Acetate | 25021-0463-01 | Sagent Pharmaceuticals | 10 × 1 | 20 |
| Octreotide Acetate | 25021-0464-01 | Sagent Pharmaceuticals | 10 × 1 | 40 |
| Octreotide Acetate | 25021-0465-01 | Sagent Pharmaceuticals | 10 × 1 | 200 |
| Octreotide Acetate | 25021-0466-05 | Sagent Pharmaceuticals | 5 | 40 |
| Octreotide Acetate | 25021-0467-05 | Sagent Pharmaceuticals | 5 | 200 |
| Octreotide Acetate | 63323-0376-01 | FreseniUS Kabi USA, LLC | 10 × 1 | 40 |
| Octreotide Acetate | 63323-0376-04 | FreseniUS Kabi USA, LLC | 10 × 1 | 40 |
| Octreotide Acetate | 63323-0377-01 | FreseniUS Kabi USA, LLC | 10 × 1 | 200 |
| Octreotide Acetate | 63323-0377-04 | FreseniUS Kabi USA, LLC | 10 × 1 | 200 |
| Octreotide Acetate | 63323-0378-05 | FreseniUS Kabi USA, LLC | 5 | 40 |
| Octreotide Acetate | 63323-0379-05 | FreseniUS Kabi USA, LLC | 5 | 200 |
| Octreotide Acetate | 67457-0239-01 | Mylan Institutional LLC | 10 × 1 | 20 |
| Octreotide Acetate | 67457-0245-01 | Mylan Institutional LLC | 10 × 1 | 40 |
| Octreotide Acetate | 67457-0246-01 | Mylan Institutional LLC | 10 × 1 | 200 |
| Octreotide Acetate | 68462-0896-10 | Glenmark Pharmaceuticals Inc., USA | 10 × 1 | 40 |
| Octreotide Acetate | 68462-0897-10 | Glenmark Pharmaceuticals Inc., USA | 10 × 1 | 200 |
| Octreotide Acetate | 71288-0566-02 | Meitheal Pharmaceuticals Inc. | 10 × 1 | 20 |
| Octreotide Acetate | 71288-0567-02 | Meitheal Pharmaceuticals Inc. | 10 × 1 | 40 |
| Octreotide Acetate | 71288-0568-02 | Meitheal Pharmaceuticals Inc. | 10 × 1 | 200 |
| Sandostatin | 00078-0180-01 | Novartis Pharmaceuticals Corporation | 10 × 1 | 20 |
| Sandostatin | 00078-0181-01 | Novartis Pharmaceuticals Corporation | 10 × 1 | 40 |
| Sandostatin | 00078-0182-01 | Novartis Pharmaceuticals Corporation | 10 × 1 | 200 |
J2354: common questions
- Is J2354 a CPT code?
- No. J2354 is a HCPCS Level II code, maintained by CMS, that identifies the drug supplied. CPT codes are five-digit numbers from the AMA that describe services. Giving the drug, for example an injection or infusion, is usually reported with a separate CPT administration code. CPT codes for drug administration.
- What NDCs are billed under J2354?
- CMS's ASP crosswalk for October 1, 2026 through December 31, 2026 lists 36 NDCs under J2354, for Octreotide Acetate and Sandostatin. The table on this page shows each one with its billing units per package.
- What is the Medicare payment limit for J2354?
- $0.574 per 25 mcg, effective October 1, 2026 through December 31, 2026, from CMS's Part B drug payment limit file. Multiply by the units billed for the allowed amount before deductible and coinsurance. It is not a coverage decision.
- What is one billing unit of J2354?
- One unit of J2354 is 25 mcg, as stated in the code's descriptor. Units to report = dose given ÷ 25 mcg. J-code billing units.